- /
- Supported exchanges
- / US
- / MCRB.NASDAQ
Seres Therapeutics Inc (MCRB NASDAQ) stock market data APIs
Seres Therapeutics Inc Financial Data Overview
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Seres Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Seres Therapeutics Inc data using free add-ons & libraries
Get Seres Therapeutics Inc Fundamental Data
Seres Therapeutics Inc Fundamental data includes:
- Net Revenue: 789 K
- EBITDA: -89 838 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-05
- EPS/Forecast: -1.88
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Seres Therapeutics Inc News
New
Sector Update: Health Care Stocks Rise Late Afternoon
Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index adding 0.8% PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Seres down after pausing investments for lead program
[An arrow pointing downwards on top of a pile of US dollar bills.] Seres Therapeutics (MCRB [https://seekingalpha.com/symbol/MCRB]) lost ~25% in the premarket on Thursday after the company announced ...
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx® platform provides high-resolution functional biological understandin...
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
2025 was a catalyst year for biotech and drug stocks. While the year began on a cautious note for the sector due to concerns over potential tariffs on pharmaceutical imports, the sector rebounded in t...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.